ML351 As Treatment For Stroke And Ischemic Brain Injury
Tech ID: 33275 / UC Case 2016-385-0

BACKGROUND

Lipoxygenases form a large family of enzymes capable of oxidizing arachidonic acid and related polyunsaturated fatty acids. One such lipoxygenase, 12/15 LOX can oxidize both the C-12 and C-15 of arachidonic acid, forming 12- or 15-hydroperosyarachidonic acid (12- or 15-HPETE). Lipoxygenases and their metabolites have been implicated in many diseases. In particular 12/15-LOX (also known as 15-LOX-1, 15-LOX, or 15-LO-1 in humans and L-12-LoX, leukocyte-type 12-LO, or L-12-LO in mice) plays a role in atherogenesis, diabetes, Alzheimer's, newborn periventricular leukomalacia, breast cancer, and stroke. Whatever the name, the protein is encoded by the gene ALOX15 in both mice and humans.

Lox inhibitors are difficult to develop due to the mouse and human homologs having different substrate and inhibitor specificities - 12/15 LOX produces predominantly 15-HETE in humans and 12-HETE in mice. So existing inhibitors are not selective for 12/15 LOX with regard to other LOX isoforms. In addition, many are strong antioxidants and therefore may result in off-target effects.

TECHNOLOGY DESCRIPTION

A collaboration between UC Santa Cruz, Boston Children’s Hospital, and the National Institutes of Health performed a systematic chemical screen for 12-LOX inhibitors. The screen revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.

Issued patents include methods and compounds.
APPLICATIONS

Potential therapeutic for:

- diabetes,
- Alzheimer's,
- newborn periventricular leukomalacia,
- breast cancer,
- stroke
- atherogenesis

Inhibition of 12/15 lipoxgenase

ADVANTAGES

- Specifically inhibits 12/15-LOX relative to 15-LOX, 12-LOX, and 5-LOX
- Low antioxidant activity
- Activity in animal models (e.g. protective in stroke model)
- Good in vivo ADME profile
- Good brain/plasma ratio (crosses BBB)

INTELLECTUAL PROPERTY INFORMATION

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Number</th>
<th>Dated</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States Of America</td>
<td>Issued Patent</td>
<td>10,287,279</td>
<td>05/14/2019</td>
<td>2016-385</td>
</tr>
<tr>
<td>European Patent Office</td>
<td>Published Application</td>
<td>3036226</td>
<td>06/29/2016</td>
<td>2016-385</td>
</tr>
<tr>
<td>Canada</td>
<td>Published Application</td>
<td>2015/027146 A1</td>
<td>02/26/2015</td>
<td>2016-385</td>
</tr>
<tr>
<td>Switzerland</td>
<td>Published Application</td>
<td></td>
<td></td>
<td>2016-385</td>
</tr>
<tr>
<td>Germany</td>
<td>Published Application</td>
<td></td>
<td></td>
<td>2016-385</td>
</tr>
<tr>
<td>France</td>
<td>Published Application</td>
<td></td>
<td></td>
<td>2016-385</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Published Application</td>
<td></td>
<td></td>
<td>2016-385</td>
</tr>
</tbody>
</table>

RELATED MATERIALS

- Discovery of ML351, a Potent and Selective Inhibitor of Human 15-Lipoxgenase - 01/13/2014
ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

15LOX1 Inhibitor Formulation Determination For IV Administration

University of California, Santa Cruz
Industry Alliances & Technology Commercialization
Kerr 413 / IATC,
Santa Cruz, CA 95064

Tel: 831.459.5415
innovation@ucsc.edu
officetofresearch.ucsc.edu/
Fax: 831.459.1658

© 2023, The Regents of the University of California
Terms of use
Privacy Notice